US 11,780,920 B2
Antibodies binding to CD3 and CD19
Anne Freimoser-Grundschober, Schlieren (CH); Maria Valeria Gonzalez Nicolini, Schlieren (CH); Ralf Hosse, Schlieren (CH); Alexander Knaupp, Penzberg (DE); Ekkehard Moessner, Schlieren (CH); Wolfgang Richter, Basel (CH); Halina Trochanowska, Schlieren (CH); Pablo Umaña, Schlieren (CH); Christian Klein, Schlieren (CH); and Inja Waldhauer, Schlieren (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Jun. 17, 2021, as Appl. No. 17/350,111.
Claims priority of application No. 20181056 (EP), filed on Jun. 19, 2020.
Prior Publication US 2022/0010014 A1, Jan. 13, 2022
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01)] 59 Claims
 
1. An antibody that binds to CD3 and CD19, wherein the antibody comprises
(a) a first antigen binding domain that binds to CD3, comprising a heavy chain variable region (VH) comprising a heavy chain complementary determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10; and
(b) a second antigen binding domain that binds to CD19, comprising
(i) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21; or
(ii) a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 28, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 29, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 30, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 32, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 33, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 34.